🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Impact of rTMS Combined With Neurorehabilitation on Lower Extremity Motor Function and Spasticity in Children With Spastic Diplegic Cerebral Palsy

RecruitingNAAges 5 Years - 18 YearsAllAnkara City Hospital Bilkent
NCT07488429 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Cerebral palsy (CP) is widely recognized as the most prevalent cause of lifelong physical disability emerging in childhood across most global populations. While international data typically reports a prevalence ranging from 1.5 to 2.5 per 1,000 live births, in our specific national context, this rate is notably higher, reaching 4.4 per 1,000. CP is defined as a heterogeneous group of permanent disorders that fundamentally disrupt the development of movement and posture. These disruptions lead to significant activity limitations and are attributed to non-progressive disturbances occurring in the developing fetal or infant brain. Beyond primary motor impairments, CP is frequently characterized by a complex constellation of associated symptoms, including sensory and perceptual deficits, cognitive impairments, communication difficulties, behavioral challenges, epilepsy, and secondary musculo

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Diagnosis of Spastic Diplegic Cerebral Palsy. * Between 5 and 18 years of age. * Cooperative and oriented (capable of following commands). * Gross Motor Function Classification System (GMFCS) Level II or III. Exclusion Criteria: * Poor general health status. * Children with severe comorbid conditions (e.g., total or partial blindness, severe lower extremity deformities, etc.). * Diagnosis of epilepsy. * History of seizures. * Presence of a cardiac pacemaker. * Presence of metal implants (specifically in the cranial and cervical regions). * Open wounds or infections at the application site. * History of botulinum toxin injection or surgical intervention within the 6 months prior to study enrollment. * History of Selective Posterior Rhizotomy (SPR) surgery.
💊

What it tests

  • TMS
📍

Where

1 site
Ankara Bilkent City Hospital
Ankara, Turkey (Türkiye)
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy